Luminex's gross profit for the
three
months ended in Mar. 2021 was $66.5 Mil. Luminex's gross profit for the trailing twelve months (TTM) ended in Mar. 2021 was $264.0 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Luminex's gross profit for the
three
months ended in Mar. 2021 was $66.5 Mil. Luminex's Revenue for the
three
months ended in Mar. 2021 was $110.7 Mil. Therefore, Luminex's Gross Margin % for the quarter that ended in Mar. 2021 was 60.04%.
Luminex had a gross margin of 60.04% for the quarter that ended in Mar. 2021 => Durable competitive advantage
During the past 13 years, the highestGross Margin % of Luminex was 70.97%. The lowest was 54.61%. And the median was 66.84%.
Warning Sign:
Luminex Corp gross margin has been in long term decline. The average rate of decline per year is -4.3%.
Luminex Gross Profit Historical Data
The historical data trend for Luminex's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Luminex's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Luminex's Gross Profit Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Luminex's Gross Profit distribution charts can be found below:
* The bar in red indicates where Luminex's Gross Profit falls into.
Luminex Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Luminex's Gross Profit for the fiscal year that ended in Dec. 2020 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $264.0 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Luminex (NAS:LMNX) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Luminex had a gross margin of 60.04% for the quarter that ended in Mar. 2021 => Durable competitive advantage
Luminex Gross Profit Related Terms
Thank you for viewing the detailed overview of Luminex's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Luminex Corp develops, manufactures, and sells proprietary biological testing technologies and products to testing laboratories. It primarily serves the life sciences industries by selling products used by laboratory professionals and clinical laboratories in performing diagnostics, drug research and discovery, and clinical tests on patients. Luminex's market segments mainly include Infectious disease, Personalized medicine, and Human genetics. It offers various solutions in diverse markets, including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, and food safety. The vast majority of the company's revenue is earned in the United States. The products offered are xMAP Products, ARIES Products and VERIGENE Products, among others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LMNX has been successfully added to your 